Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience

References

• Gisondi P, Geat D, Armeni P, et al. Cost per responder of adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis. Expert Opin Biol Ther. 2022;26:1–5.
   Google Scholar
• Gisondi P, Geat D, Maurelli M, et al. Cost per responder analysis of secukinumab versus adalimumab in the treatment of psoriatic disease. Vaccines. 2022;10(5):646.
   PubMed Web of Science ®Google Scholar
• Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4(2):559–568.
   PubMedGoogle Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris-update 2015-short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–2294.
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Mason E, et al. Real-Life effectiveness of adalimumab biosimilars in patients with chronic plaque psoriasis. Dermatol Ther. 2022;12(6):1303–1311.
   PubMed Web of Science ®Google Scholar
• Esposti LD, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics. 2018;12:151–158.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Maurelli M, et al. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis. 2022;12:213–220.
   PubMed Web of Science ®Google Scholar
• Vogler S, Schneider P, Zuba M, et al. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:625296.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Geat D, Conti A, et al. TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Rev Clin Immunol. 2020;16(6):591–598.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.gazzettaufficiale.it/eli/id/2016/11/11/16A07913/sg.
   Google Scholar
• Available from: https://www.gazzettaufficiale.it/eli/id/2021/07/28/21A04520/SG#:∼:text=Prezzo%20al%20pubblico%20(iva%20inclusa,E%20(in%20base%2010.)
   Google Scholar
• Available from: http://azero.veneto.it/public/alboOnline.xhtml?pageType=all.
   Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
   PubMed Web of Science ®Google Scholar
• Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, et al. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107(7):577–590.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–881.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535.
   PubMedGoogle Scholar
• Ozkok Akbulut T, Topaloglu Demir F, Oguz Topal I, et al. Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study. Int J Dermatol. 2021;60(9):1140–1147.
   PubMed Web of Science ®Google Scholar
• Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med. 2020;7:625755.
   Web of Science ®Google Scholar
• Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90(6):711–716.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci. 2016;17(2):217.
   PubMed Web of Science ®Google Scholar
• Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656–662.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Wan J, Zhang H, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study. J Am Acad Dermatol. 2021;84(6):1636–1643.
   PubMed Web of Science ®Google Scholar
• Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74–79.
   PubMed Web of Science ®Google Scholar
• von Stülpnagel CC, Augustin M, Düpmann L, et al. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases – a systematic review. J Eur Acad Dermatol Venereol. 2021;35(11):2166–2184.
   PubMed Web of Science ®Google Scholar
• Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018;32(11):1930–1939.
   PubMed Web of Science ®Google Scholar